American CryoStem Corporation (CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today released Summary corporate and financial highlight information regarding the Company’s year ending September 30, 2016.

1.
AMERICAN CRYOSTEM 2016 YEAR END UPDATE
EATONTOWN, NJ / ACCESSWIRE / January 4, 2017 / American CryoStem Corporation (CRYO) a
leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular
technologies for the Regenerative and Personalized Medicine industries, today released Summary
corporate and financial highlight information regarding the Company’s year ending September 30, 2016;
• The Company's Total Revenue increased 75% in Fiscal 2016 versus 2015
• Contributing to the Total Revenue increase for Fiscal 2016, International Revenue increased 19% in
Fiscal 2016 versus Fiscal 2015
• Accounts Receivable increased 15% in Fiscal 2016 versus Fiscal 2015
• Tissue storage and processing increased 289% in Fiscal 2016 versus Fiscal 2015
• Research & Development decreased 60% in Fiscal 2016 compared to Fiscal 2015 which is attributed
to; the completion of certain research projects
• Professional fees increased (principally legal and accounting) 130% in Fiscal 2016 compared to
Fiscal 2015 due to an increase in legal expenses for the prosecution of our international patent
portfolio, and optimization and scale up work associated with the licensing of our patented cell
culture media, ACSelerate Max, to PeproTech in 2016
“American CryoStem’s 2016 results reflect an increased interest by the medical and patient populations to
seek out natural cosmetic solutions and products, and cellular therapies as alternative treatments for those
that are not responding to traditional treatment solutions. We believe that we are well positioned to respond
to these increased interests and look forward to continuing our year over year positive results” stated
Anthony Dudzinski, COO.
John S. Arnone, CEO stated, “We are very optimistic about the state of the Regenerative Medicine Industry
in the United States and globally as we enter 2017. We have seen a steady increase of new patients storing
their stem cells for future use and physicians utilizing our products and service in 2016. We are in
discussions for new global territories with licensees seeking to establish our adipose tissue (fat) based
collect-process-store, stem cell platform in their country”. This increased interest in cellular therapies is
evidenced in eight thousand (8,000+) plus clinical trials currently registered with ClinicalTrials.gov focused
on adipose tissue and its derivatives which include; adipose tissue (2,083), adult stem cells (5,709), adipose
derived stem cells, mesenchymal stem cells and stromal vascular fraction (SVF). Arnone further stated, “In
2017 we look forward to expanding our US based physician network, patient stem cell storages and
increasing our global laboratory footprint as regenerative and personalized medicine applications become
main stream”.
FOR MORE INFORMATION:
American CryoStem
732-747-1007 or via email
at info@americancryostem.com

2. In 2017 management intends to continue its focus on increasing revenue, reducing costs and plans to begin a
comprehensive investor and customer relations programs in Fiscal 2017.
About American CryoStem Corporation
American CryoStem Corporation (OTCQB: CRYO); was founded in 2008, and has evolved to become a
biotechnology pioneer, standardizing adipose tissue derived technologies (Adult Stem Cells) for the fields of
Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, clinical
laboratory in New Jersey and licensed laboratories in Hong Kong, China and Tokyo, Japan, operating on our
proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of
adipose tissue (fat) and adipose derived stem cells (ADSCs) for current or future use in regenerative medicine.
CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology
which supports a growing pipeline of stem cell applications and biologic products. We are leveraging our
proprietary, IRB approved, FDA compliant platform and a developed product portfolio to create a domestic
and global footprint of licensed laboratory affiliates, physicians networks and research organizations who
purchase tissue collection, processing and storage consumables from our Company. Our laboratory stem cell
bank/line products are characterized adult human Mesenchymal Stem Cell (MSC’s) derived from adipose
tissue that work in conjunction with our 13 patented (non-animal) medium lines. The Company’s R&D efforts
are focused on university and private collaborations to discover, develop and commercialize ADSC therapies
by utilizing our standardized collection-processing-storage methodology and laboratory products combined
with synergistic technologies to create jointly developed regenerative medicine applications and intellectual
property.
For further detailed corporate or Regenerative Medicine information please visit:
www.americancryostem.com, request by email at info@americancryostem.com or phone 732-747-1007
This press release may contain forward-looking statements, including information about
management's view of American CryoStem Corporation’s (“the Company”) future expectations, plans
and prospects. In particular, when used in the preceding discussion, the words "believes," "expects,"
"intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to
identify forward-looking statements. Any statements made in this press release other than those of
historical fact, about an action, event or development, are forward-looking statements. These
statements involve known and unknown risks, uncertainties and other factors, which may cause the
results of the Company, its subsidiaries and concepts to be materially different than those expressed
or implied in such statements. Unknown or unpredictable factors also could have material adverse
effects on the Company’s future results. The forward-looking statements included in this press
release are made only as of the date hereof. The Company cannot guarantee future results, levels
of activity, performance or achievements. Accordingly, you should not place undue reliance on these
forward-looking statements. Finally, the Company undertakes no obligation to update these
statements after the date of this release, except as required by law, and also takes no obligation to
update or correct information prepared by third parties that are not paid for by American CryoStem
Corporation.